Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00523380 | Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer | PHASE2 | COMPLETED | 10 | — | — | Oct 4, 2007 | Jan 7, 2009 | Mar 1, 2017 | 7 | France, Germany |
| NCT00617253 | Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients | PHASE2 | COMPLETED | 9 | — | — | Jul 12, 2007 | Jun 30, 2008 | Mar 1, 2017 | 5 | Germany, Netherlands |
| NCT00336986 | Efficacy Study of IL-21 to Treat Metastatic Melanoma | PHASE2 | COMPLETED | 54 | — | — | Sep 1, 2004 | Oct 1, 2007 | Aug 14, 2023 | 7 | Australia |
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | EXPERIMENTAL | - |
| C | EXPERIMENTAL | - |
| D | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| recombinant interleukin-21 | DRUG | Administered i.v. in treatment cycles of 28 days. |
| caelyx (pegylated liposomal doxorubicin) | DRUG | Administered i.v. in treatment cycles of 28 days. |
| sunitinib | DRUG | Hard gelatine capsules, 12.5 mg |
Inclusion Criteria: * Advanced epithelial Ovarian Cancer (stage IIB-IV) * Persistent or progressive disease after or relapse within one year of completion of first line therapy * Measurable or assessable disease * Eastern Cooperative Oncology Group status less than or equal to 2 Exclusion Criteria...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |